A Phase 4 interventional study of Istalol and Optive and Alphagan in Ocular Hypertension and Open-Angle Glaucoma, sponsored by Bp Consulting, Inc. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2008-12-04.
Sponsored by Bp Consulting, Inc · Phase 4, Interventional, and Treatment
To assess the additional benefit of common adjunctive classes on the diurnal IOP curve in patients assessed as needing additional treatment to reach target intraocular pressure (IOP). To demonstrate superiority of IOP control with Istalol 0.5% QD compared to Brimonidine Tartrate 0.2% BID as adjunctive therapy in adults with uncontrolled IOP's (determined by P.I. based on target pressures) currently treated with Latanoprost 0.05% in the study eye(s).
1,818 studies on the registry are indexed under Glaucoma; 231 are open to participants now.
This study's planned enrollment of 40 is below the median of 65 across 1,272 interventional studies indexed under Glaucoma.
Browse Glaucoma studies →Bp Consulting, Inc is the lead sponsor of 10 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Alphagan
Drug: Alphagan
Istalol and Optive
Drug: Istalol and Optive
Istalol: one drop a day for 28 days Optive: one drop a day for 28 days
Alphagan: two drops a day for 28 days
Trough and peak intraocular pressure
Time frame: 2-4 months
Tolerability of study medication
Time frame: 2-4 months
This study is completed, as verified in Dec 2008. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Bp Consulting, Inc